G1 Therapeutics
700 Park Offices Drive
Suite 200
Research Triangle Park
North Carolina
27709
United States
Website: http://www.g1therapeutics.com/
231 articles about G1 Therapeutics
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 01, 2023
9/1/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 6,800 shares of G1’s common stock and 3,300 restricted stock units to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
8/2/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the second quarter ended June 30, 2023.
-
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
7/31/2023
G1 Therapeutics, Inc. (Nasdaq: GTHX) today announced the publication of real world outcomes data from published and new unpublished studies showing the potential of trilaciclib to reduce single and multilineage myelosuppressive events associated with chemotherapy, cytopenia-related healthcare utilization, and hospitalizations in adults being treated for extensive stage small cell lung cancer (ES-SCLC).
-
G1 Therapeutics to Participate in Two August 2023 Investor Conferences
7/31/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it will participate in two August investor conferences.
-
G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
7/26/2023
G1 Therapeutics, Inc. will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on Wednesday August 2, 2023, at 8:30 a.m. ET.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2023
7/6/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 5,600 shares of G1’s common stock and 2,800 restricted stock units to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
6/4/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with early-stage triple-negative breast cancer prior to receiving trilaciclib and neoadjuvant therapy.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2023
6/1/2023
G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
5/22/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer.
-
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
5/16/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, described recently presented real-world data that confirm a consistent risk of myelosuppressive events across patients with small cell lung cancer being treated with chemotherapy.
-
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
5/10/2023
G1 Therapeutics, Inc. today presented preliminary results from 30 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate (ADC), sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
-
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
5/3/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the first quarter ended March 31, 2023.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 01, 2023
5/1/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 4,200 shares of G1’s common stock and 2,000 restricted stock units to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
4/26/2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter 2023 on Wednesday May 3, 2023, at 8:30 a.m. ET.
-
G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
4/11/2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey and other members of the Executive Team will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference.
-
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
3/1/2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2022.
-
G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
2/28/2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1’s Chief Executive Officer Jack Bailey will participate in the moderated Breast and Lung Cancer Panel during the Cowen 43rd Annual Health Care Conference.
-
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
2/22/2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2022 on Wednesday, March 1, 2023, at 8:30 a.m. ET.
-
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
2/13/2023
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-primary endpoints related to severe neutropenia with statistical significance; however, early anti-tumor efficacy data, including overall response rate (ORR) and preliminary measures of survival, favored the placebo arm.
-
First Prescription for COSELA® (trilaciclib) Issued in China
2/9/2023
Simcere Pharmaceutical Group Limited announce a significant milestone in the fight against cancer with the issuance of the first prescription for COSELA® (trilaciclib) in China.